The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Genomic Health been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.

Genomic Health is a member of the Medical sector. This group includes 841 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.

The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. GHDX is currently sporting a Zacks Rank of #1 (Strong Buy).

Over the past 90 days, the Zacks Consensus Estimate for GHDX's full-year earnings has moved 96.65% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

According to our latest data, GHDX has moved about 113.16% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 1.12% on a year-to-date basis. This means that Genomic Health is performing better than its sector in terms of year-to-date returns.

Breaking things down more, GHDX is a member of the Medical - Biomedical and Genetics industry, which includes 341 individual companies and currently sits at #66 in the Zacks Industry Rank. On average, this group has lost an average of 15.77% so far this year, meaning that GHDX is performing better in terms of year-to-date returns.

Investors with an interest in Medical stocks should continue to track GHDX. The stock will be looking to continue its solid performance.